TG Therapeutics

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

TG Therapeutics secures FDA approval for BRIUMVI, poised for growth

TG Therapeutics' Q4 2022 performance reflects a solid financial position with a focus on efficient capital management and commercial execution.
Strengths lie in FDA approval for BRIUMVI, positive launch progress, and commitment to supporting the MS community, positioning the company for growth.
Challenges include sustaining momentum, achieving broad payer coverage, managing expenses, and navigating complexities related to clinical trials.
Opportunities exist in further data analysis, market expansion, community engagement, and strategic investments, driving future growth and differentiation.

TG Therapeutics excels with BRIUMVI launch, eyes European expansion

TG Therapeutics demonstrated strong financial stability and strategic expense management in Q1 2023, despite reporting a net loss, showcasing resilience and efficient operations.
BRIUMVI's early success in the US market, positive feedback from healthcare providers, and progress in payer coverage position the product as a competitive and promising offering in the MS treatment class.
While facing decisions on international expansion and expense optimization, TG Therapeutics remains committed to serving the MS community and improving patient outcomes with BRIUMVI.
The company's focus on market access, product efficacy, and financial prudence sets a solid foundation for future growth and success in the competitive pharmaceutical landscape.

TG Therapeutics reports stellar Q2 performance and eyes global expansion

TG Therapeutics showcased robust financial performance and market acceptance of Briumvi in Q2 2023.
While facing challenges like revenue lag and potential market competition, the company remains well-positioned.
Opportunities lie in expanding market reach, product offerings, and maximizing the potential of Briumvi.
Overall, TG Therapeutics' strategic partnerships and positive market feedback position it for continued success.

TG Therapeutics excels in Q3 with BRIUMVI's market success

TG Therapeutics had a strong Q3 performance, driven by BRIUMVI's success and revenue exceeding expectations. The company is well-positioned with a healthy cash reserve and plans for market expansion. Challenges include potential competition from BTK drugs and seasonal market fluctuations.

TG Therapeutics excels in Q4 with BRIUMVI, eyes strong growth

TG Therapeutics demonstrated robust financial performance and strategic growth plans during the Q4 2023 earnings call, driven by the successful launch of BRIUMVI.
While facing challenges such as optimizing the infusion process and managing expenses, the company's focus on innovation and market expansion positions it for future success.
With a strong emphasis on commercialization, patent protection, and revenue targets, TG Therapeutics shows promising potential for sustained growth and value creation.

TG Therapeutics reports robust Q1 results, eyes growth opportunities

TG Therapeutics' Q1 performance reflects strong revenue growth driven by Briumvi's success and strategic investments in awareness and commercialization.
While facing challenges in market share growth and profitability, the company's focus on innovation and partnerships positions it well for future opportunities.
Maintaining a healthy financial position and a commitment to R&D underscore TG Therapeutics' resilience and potential for continued growth in the autoimmune therapy space.

TG Therapeutics excels in Q2, raises guidance and focuses on growth

TG Therapeutics delivered a strong Q2 performance with notable achievements in sales, R&D, and financial stability. While facing challenges related to internal controls and VA contract impact, the company is well-positioned to capitalize on opportunities for growth through market expansion and strategic initiatives.

TG Therapeutics reports robust Q3 earnings and outlines growth strategies

TG Therapeutics (TGTX) delivered a strong performance in Q3 2024, driven by the success of BRIUMVI and strategic growth initiatives.
While facing challenges in market competition and product development, TGTX remains focused on innovation, expansion, and maximizing shareholder value.
The company's financial strength, successful partnerships, and clear growth strategies position TGTX for continued success and future growth in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics achieved approval of Briumvi, a CD20 antibody for relapsing MS, a needed win following the withdrawal of their only other product. Briumvi has comparable data but a lower cost than other CD20 inhibitors, possibly making it an attractive treatment option.

TG Therapeutics' Briumvi Has Potential For Growth In A Crowded Market

ICER published a report saying TG Therapeutics, Inc.'s briumvi is overpriced. It has said this for other major drugs over the years, with no impact on their bottom lines.

TG Therapeutics: That ICER Report Doesn't Bother Me

NEW YORK, March 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology (AAN) annual meeting, being held April 22 – 27, 2023 in Boston, Massachusetts. Abstracts are now available online and can be accessed within the AAN annual meeting program at www.aan.com/msa/public/events/index/45. Details of the presentations are outlined below.

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual Meeting

TG Therapeutics, Inc. (NASDAQ:TGTX ) Q4 2022 Earnings Conference Call February 28, 2023 8:30 AM ET Company Participants Jenna Bosco – Investor Relations Michael Weiss – Chairman and Chief Executive Officer Adam Waldman – Chief Commercialization Officer Sean Power – Chief Financial Officer Conference Call Participants Josh Schimmer – Evercore ISI Ed White – H. C. Wainwright Prakhar Agrawal – Cantor Fitzgerald Sahil Kazmi – B.

TG Therapeutics, Inc. (TGTX) Q4 2022 Earnings Call Transcript

Conference call to be held today, Tuesday, February 28, 2023, at 8:30 AM ET Conference call to be held today, Tuesday, February 28, 2023, at 8:30 AM ET

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results

Conference call to be held Tuesday, February 28, 2023 at 8:30 AM ET Conference call to be held Tuesday, February 28, 2023 at 8:30 AM ET

TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2022 Financial Results and Business Update

NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ublituximab-xiiy) in adult patients with relapsing forms of multiple sclerosis (RMS), presented at the 2023 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum. Links to each of the presentations are included below.

TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

Growth stock TG Therapeutics has surged 80% after FDA approval for its multiple sclerosis treatment. The post Biotech Growth Stock Boosted By FDA Approval For Multiple Sclerosis Treatment appeared first on Investor's Business Daily.

Biotech Growth Stock Boosted By FDA Approval For Multiple Sclerosis Treatment

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ublituximab) in adult patients with relapsing forms of multiple sclerosis (RMS), at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 23 – 25, 2023, in San Diego, California. Abstracts are now available online and can be accessed on the ACTRIMS meeting website at www.forum.actrims.org. Details of the presentations are outlined below.

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

It's been a while since the Marketbeat team flagged a hot stock that had already logged a 300% rally but looked like it was going to go higher. But the New York-headquartered TG Therapeutics Inc (NASDAQ: TGTX) is worth every word.

TG Therapeutics Stock 300% Rally Has Legs Yet

After a year of churn and doldrums, TG Therapeutics, Inc. finally got approval for, and launched, briumvi or ublituximab in RRMS. I am trying to decide what to do with my TG Therapeutics shares, now that I have just broken even after doubling down twice.

TG Therapeutics: Strategy After Briumvi Launch

NEW YORK, Jan. 26, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the commercial launch of BRIUMVI™ (ublituximab-xiiy), for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis

Wilmington, Delaware--(Newsfile Corp. - January 23, 2023) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of TG Therapeutics, Inc. (NASDAQ: TGTX) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-tg-therapeutics-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TG Therapeutics, Inc.

TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

TG Therapeutics (TGTX) Soars 8.7%: Is Further Upside Left in the Stock?

TG Therapeutics (TGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

TG Therapeutics (TGTX) Upgraded to Buy: What Does It Mean for the Stock?

Presentation scheduled for Monday, January 9, 2023 at 9:45 AM PT Presentation scheduled for Monday, January 9, 2023 at 9:45 AM PT

TG Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

TG Therapeutics, Inc. is set to launch Briumvi with an experienced in-house team. There are several factors conducive to launch success. Nevertheless, uncertainty remains.

TG Therapeutics: Ramifications Of Briumvi Approval

Boeing

Caterpillar

Celsius Holdings

Clearfield

Vita Coco

Chevron

DocGo

Enphase Energy

JPMorgan Chase & Co

McDonald's

Merck

Noble Corp PLC

Northern Oil and Gas

Nuvalent

Permian Basin Royalty Trust

Pinduoduo Inc - ADR

Tidewater

Mammoth Energy Services

Visa

Vipshop Hlds

Viridian Therapeutics

Verizon

Wave Life Sciences

Two new Breakout Stocks for Week 1 with better than 10% short-term upside potential and two Dow 30 Picks. Average cumulative returns for 2022 reached +142.69% YTD. The streak of weekly picks gaining over 10% in less than a week of trading days has reached 235 out of 293 trading weeks (80.4%) not counting multiple gainers.

MDA Breakout Stocks Week 1 - January 2023: High-Frequency Gainers To Give You An Edge

The company scored a giant victory on the regulatory front.

Why TG Therapeutics Stock Was a Solid Winner This Week

The FDA approves TG Therapeutics' (TGTX) Briumvi (ublituximab-xiiy) for treating relapsing forms of multiple sclerosis. The company plans to launch the drug in the first quarter of 2023.

TG Therapeutics (TGTX) Gets FDA Nod for Multiple Sclerosis Drug

TG Therapeutics Inc TGTX shares are trading higher by 9.34% to $9.25 Thursday morning. The company on Wednesday revealed FDA approval of ublituximab.

What's Going On With TG Therapeutics Shares - TG Therapeutics (NASDAQ:TGTX)

Pfizer

The stock market lost ground as economic worries persist.

Pfizer Makes Progress, but This Biotech Was Wednesday's Big Winner

BRIUMVI is the first and only anti-CD20 monoclonal antibody approved for patients with relapsing forms of multiple sclerosis that can be administered in a one-hour infusion twice-a-year following the starting dose

TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)

TG Therapeutics is approaching its Prescription Drug User Fee Act (PDUFA) goal date of December 28, 2022, for ublituximab for the treatment of relapsing forms of multiple sclerosis (RMS). It appears that TG will launch ublituximab under the trade name "BRIUMVI".

TG Therapeutics: Ublituximab Could Achieve $1 Billion In Annual Sales By Year-End 2024

TG Therapeutics, Inc. management has been focusing on the company's most valuable (multiple sclerosis) franchises in an effort to turn around. TG Therapeutics' ublituximab generated extremely strong Phase 2 and Phase 3 multiple sclerosis data.

News for TG Therapeutics Stock (TGTX)